First-in-Man Study: Safety and Efficacy of INC-1 Bare Metal Stent in the Novo Coronary Lesions.
NCT ID: NCT03375411
Last Updated: 2022-10-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2017-12-30
2019-01-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Infinnium-Core™ Registry for the Treatment of Patients With De Novo Coronary Lesions
NCT00936780
Comparison of Drug Eluting Balloon and Drug Eluting Stent
NCT01539603
Paclitaxel Releasing Balloon in Patients Presenting With In-Stent Restenosis
NCT00961181
Paclitaxel Eluting Balloon After Bare Metal Stent Implantation vs. Drug-Eluting Stent in St Elevation Myocardial Infarction
NCT03610347
CVT-ISR First in Human Trial for Coronary In-Stent Restenosis
NCT05731700
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Ischemic heart disease together with cerebral vascular events is the main cause of, adding 15 million deaths per year. Percutaneous revascularization is the gold standard choice in many of the variants of presentation of ischemic heart disease, the implantation of Stents is the most used method.
Nowadays more and more countries start their own research and development of novel devices in order to reduce cost.
Research question: Is the INC1 Bare Metal Stent safe and effective for the treatment of de novo coronary lesions in humans? Hypothesis: The INC1 Bare-metal Stent is safe and effective for the treatment of de novo coronary lesions in humans
The INC1 Bare metal Stent is a 70uCoCr
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
INC1-Bare metal stent
Percutaneous coronary implantation of the device (Stent INC-1) following the standard procedure of stent placement
Stent INC1
Coronary intervention with conventional angioplasty technique but with a novel bare metal stent.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Stent INC1
Coronary intervention with conventional angioplasty technique but with a novel bare metal stent.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* From 18 to 75 years
* Stable ischemic heart disease.
* Live less than 300 km from the Institution
* Single coronary artery disease with a single coronary lesion
* Stenosis of 50 to 90% of the lumen of the vessel to be treated.
* Lesions less than 20 mm long
* Reference lumen of the vessel to be treated greater than 2.5mm and less than 4.5mm
Exclusion Criteria
* Lesions greater than 90% of the lumen.
* Non-dilatable lesion with conventional balloons.
* Contraindication for dual antiplatelet therapy.
* Creatinine clearance less than 45ml / min.
* Calcification from moderate to severe.
* Multivessel coronary artery disease.
* Chronic total occlusion.
* Cardiogenic shock or hemodynamic instability.
* Left ventricular ejection fraction less than 30%.
* Valvular disease of moderate to severe.
* Coronary disease in bifurcation.
* Probable or definite presence of thrombus in the lesion.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GSE Biomedical
OTHER
Medstent SA de CV.
UNKNOWN
Instituto Nacional de Cardiologia Ignacio Chavez
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gian Manuel Jiménez Rodríguez
Clinical investigator assistant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gian Manuel Jiménez Rodríguez
Role: PRINCIPAL_INVESTIGATOR
Interventional Cardiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto Nacional de Cardiología
Mexico City, , Mexico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17-1036
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.